新型冠状病毒肺炎合并代谢综合征的研究进展
1. 杭州医学院, 公共卫生学院, 浙江杭州 310059
2. 杭州医学院, 医学影像学院, 浙江杭州 310059
| 摘 要： | 新型冠状病毒肺炎是由严重急性呼吸综合征冠状病毒2引起的，在这些感染病毒的患者中，合并代谢综合征最为常见。代谢综合征是指机体内多种代谢紊乱的病理状态，常见表现为肥胖、高血压、高血糖等一种或多种症状。本文收集2020-2023年国内外关于新型冠状病毒患者合并代谢综合征的相关研究文献，对感染新型冠状病毒患者合并肥胖、高血压、高血糖等代谢综合征的流行特点及代谢综合征患者易感新型冠状病毒肺炎的可能机制进行综述，具体机制尚不明确，主要涉及血管紧张素转换酶2、促炎性细胞因子等一系列途径，发现合并患有代谢综合征的新型冠状病毒肺炎患者，其预后不良情况和死亡风险增加，这对患者治疗用药情况产生较大影响。提出应关注新型冠状病毒肺炎合并代谢综合征患者的治疗及预后情况的研究，并深入开展相关研究，同时为新型冠状病毒肺炎合并代谢综合征患者的治疗及管理提供相关理论参考。 |
| 关 键 词： | 新型冠状病毒肺炎; 代谢综合征; 肥胖; 高血压; 糖尿病 |
| DOI： | 10.57237/j.mrf.2023.03.006 |
View:
Downloads:
收稿日期: 2023-07-04
接受日期: 2023-09-05
在线出版日期: 2023-09-08
Research Progress of Comorbidity of Coronavirus Disease 2019 with Metabolic Syndrome
1. School of Public Health, Hangzhou Medical College, Hangzhou 310059, China
2. School of Medical Imaging, Hangzhou Medical College, Hangzhou 310059, China
| Abstract: | Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2. Among these patients infected with the virus, metabolic syndrome is the most common. Metabolic syndrome refers to the pathological state of various metabolic disorders in the body, which is commonly manifested as one or more symptoms such as obesity, hypertension and hyperglycemia. This article collects relevant research literature on COVID-19 patients with metabolic syndrome at home and abroad from 2020 to 2023, and reviews the epidemiological characteristics of COVID-19 patients with obesity, hypertension, hyperglycemia and other metabolic syndromes and the possible mechanism of COVID-19 susceptibility in patients with metabolic syndrome. The specific mechanism is not clear, mainly involving a series of pathways such as angiotensin-converting enzyme 2 and pro-inflammatory cytokines. It is found that patients with COVID-19 combined with metabolic syndrome have poor prognosis and increased risk of death, which has a great impact on the treatment and medication of patients. It is proposed that attention should be paid to the research on the treatment and prognosis of patients with COVID-19 complicated with metabolic syndrome, and relevant research should be carried out in depth. At the same time, it provides relevant theoretical reference for the treatment and management of patients with COVID-19 complicated with metabolic syndrome. |
| Keywords: | COVID-19; Metabolic Syndrome; Obesity; Hypertension; Hyperglycemia |
参考文献
| [1] | 王亚莎. 代谢综合征的代谢组学研究进展 [J]. 继续医学教育, 2021, 35 (09), 97-99. |
| [2] | 蔡瑞雪, 巢健茜, 孔令燕, 等.南京市老人代谢综合征流行病学调查研究 [J]. 中国预防医学杂志, 2019, 20 (11), 1009-1013. |
| [3] | Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020 [J]. MMWR Morb Mortal Wkly Rep, 2020, 69 (15): 458-464. |
| [4] | Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China [J]. JAMA, 2020, 323 (11). |
| [5] | Alamdari NM, Rahimi FS, Afaghi S, et al. The impact of metabolic syndrome on morbidity and mortality among intensive care unit admitted COVID-19 patients [J]. Diabetes Metab Syndr, 2020, 14 (6): 1979-1986. |
| [6] | Wu Z, Mcgoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention [J]. JAMA, 2020, 323 (13): 1239-1242. |
| [7] | Yanai H. Metabolic Syndrome and COVID-19 [J]. Cardiol Res, 2020, 11 (6): 360-365. |
| [8] | Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area [J]. JAMA, 2020, 323 (20): 2052-2059. |
| [9] | Ghoneim S, Butt MU, Hamid O, et al. The incidence of COVID-19 in patients with metabolic syndrome and non-alcoholic steatohepatitis: A population-based study [J]. Metabol Open, 2020, 8: 100057. |
| [10] | Mohamadian M, Chiti H, Shoghli A, et al. COVID-19: Virology, biology and novel laboratory diagnosis [J]. J Gene Med, 2021, 23 (2). |
| [11] | Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding [J]. The Lancet, 2020, 395 (10224): 565-574. |
| [12] | Voto C, Berkner P, Brenner C. Overview of the Pathogenesis and Treatment of SARS-CoV-2 for Clinicians: A Comprehensive Literature Review [J]. Cureus, 2020, 12 (9). |
| [13] | Tay MZ, Poh CM, Rénia L, et al. The trinity of COVID-19: immunity, inflammation and intervention [J]. Nat Rev Immunol, 2020, 20 (6): 363-374. |
| [14] | De Groot CJ, Poitou Bernert C, Coupaye M, et al. Clinical management of patients with genetic obesity during COVID-19 pandemic: position paper of the ESE Growth & Genetic Obesity COVID-19 Study Group and Rare Endo-ERN main thematic group on Growth and Obesity [J]. Endocrine, 2021, 71 (03): 1-10. |
| [15] | Fabian Sanchis-Gomar, Carl J Lavie, Mandeep R Mehra, et al. Obesity and Outcomes in COVID-19: When an Epidemic and Pandemic Collid [J]. Mayo Clin Proc, 2020, 7; 95 (7): 1445-1453. |
| [16] | Lopez-Reyes A, Martinez-Armenta C, Espinosa-Velazquez R, et al. NLRP3 Inflammasome: The Stormy Link Between Obesity and COVID-19 [J]. Front Immunol, 2020, 11: 570251. |
| [17] | Sharma JR, Yadav UCS. COVID-19 severity in obese patients: Potential mechanisms and molecular targets for clinical intervention [J]. Obes Res Clin Pract, 2021, 15 (2): 163-171. |
| [18] | Ryan PM, Caplice NM. Is Adipose Tissue a Reservoir for Viral Spread, Immune Activation, and Cytokine Amplification in Coronavirus Disease 2019? [J]. Obesity (Silver Spring), 2020, 28 (7): 1191-1194. |
| [19] | Kassir R. Risk of COVID-19 for patients with obesity [J]. Obes Rev, 2020, 21 (6). |
| [20] | Gathiram P, Mackraj I, Moodley J. The Renin-Angiotensin System, Hypertension, and SARS-CoV-2 Infection: a Review [J]. Curr Hypertens Rep, 2021, 23 (4): 17. |
| [21] | Gheblawi M, Wang K, Viveiros A, et al. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2 [J]. Circ Res, 2020, 126 (10): 1456-1474. |
| [22] | Codo AC, Davanzo GG, Monteiro LB, et al. Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1α/Glycolysis-Dependent Axis [J]. Cell Metab, 2020, 32 (3): 498-499. |
| [23] | Maddaloni E, Buzzetti R. Covid-19 and diabetes mellitus: unveiling the interaction of two pandemics [J]. Diabetes Metab Res Rev, 2020. |
| [24] | Moore JB, June CH. Cytokine release syndrome in severe COVID-19 [J]. Science, 2020, 368 (6490): 473-474. |
| [25] | Wang J, Meng W. COVID-19 and diabetes: the contributions of hyperglycemia [J]. J Mol Cell Biol, 2021, 12 (12): 958-962. |
| [26] | JoseRJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation [J]. The Lancet Respiratory Medicine, 2020, 8 (6). |
| [27] | 冯金章, 刘锁红, 冯俊芳, 等. 代谢综合征的病因及防治研究进展 [J]. 内蒙古民族大学学报(自然科学版), 2020, 35 (Issue): 525-528. |
| [28] | Sohaip Kabashneh, Hammad Ali, Samer Alkassis. Multi-Organ Failure in a Patient With Diabetes due to COVID-19 With Clear Lungs [J]. Cureus, 2020; 12 (5): e8147. |
| [29] | Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) [J]. Mil Med Res, 2020, 7 (1): 1-22. |
| [30] | Kario K, Morisawa Y, Sukonthasarn A, et al. COVID-19 and hypertension-evidence and practical management: Guidance from the HOPE Asia Network [J]. J Clin Hypertens (Greenwich), 2020, 22 (7): 1109-1119. |
| [31] | Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19 [J]. The Lancet Diabetes & Endocrinology, 2020, 8 (6): 546-550. |
| [32] | Armitage R, Nellums LB. COVID-19 and the consequences of isolating the elderly [J]. Lancet Public Health, 2020, 5 (5). |
| [33] | Santini ZI, Jose PE, York Cornwell E, et al. Social disconnectedness, perceived isolation, and symptoms of depression and anxiety among older Americans (NSHAP): a longitudinal mediation analysis [J]. Lancet Public Health, 2020, 5 (1). |
| [34] | 王燕. “互联网+健康管理”模式对体检血脂异常人群院外健康生活方式的影响 [J]. 内蒙古医学杂志, 2020, 52 (08): 926-928. |
| [35] | Pavlov VA. The evolving obesity challenge: targeting the vagus nerve and the inflammatory reflex in the response [J]. Pharmacol Ther, 2020, 222: 107794. |
| [36] | Popkin BM, Du S, Green WD, et al. Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships [J]. Obes Rev, 2020, 21 (11). |
| [37] | Bansal R, Gubbi S, Muniyappa R. Metabolic Syndrome and COVID 19: Endocrine-Immune-Vascular Interactions Shapes Clinical Course [J]. Endocrinology, 2020, 161 (10). |
| [38] | Tadic M, Cuspidi C, Mancia G, et al. COVID-19, hypertension and cardiovascular diseases: Should we change the therapy? [J]. Pharmacol Res, 2020, 158: 104906. |
| [39] | Pedrosa MA, Valenzuela R, Garrido-Gil P, et al. Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19 [J]. Clin Sci (Lond), 2021, 135 (3): 465-481. |
| [40] | Johnson BS, Laloraya M. A cytokine super cyclone in COVID-19 patients with risk factors: the therapeutic potential of BCG immunization [J]. Cytokine Growth Factor Rev, 2020, 54: 32-42. |
| [41] | Costa FF, Rosário WR, Ribeiro Farias AC, et al. Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies [J]. Diabetes Metab Syndr, 2020, 14 (5): 809-814. |
| [42] | 赵瑞, 肖暖. 健康中国背景下体医融合干预在慢性病管理中的应用 [J]. 医学信息, 2021, 34 (04): 67-70. |
| [43] | Lim S, Bae JH, Kwon HS, et al. COVID-19 and diabetes mellitus: from pathophysiology to clinical management [J]. Nat Rev Endocrinol, 2021, 17 (1): 11-30. |
| [44] | Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19 [J]. Diabetes Metab Res Rev, 2020. |
| [45] | Stoian AP, Papanas N, Prazny M, et al. Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights [J]. J Cardiovasc Pharmacol Ther, 2020, 25 (6): 494-496. |
| [46] | Jornayvaz FR, Assouline B, Pugin J, et al. Extremely high-dose insulin requirement in a diabetic patient with COVID-19: a case report [J]. BMC Endocr Disord, 2020, 20 (1). |
| [47] | Schmidt NM, Wing PaC, Mckeating JA, et al. Cholesterol-modifying drugs in COVID-19 [J]. Oxf Open Immunol, 2020, 1 (1). |
